natgillin/translations-raw huggingface dataset:
Acetylsalicylsyre, der findes i mange smertestillende og feberstillende lægemidler, samt andre smertestillende, inflammationsdæmpende og feberstillende lægemidler: ibuprofen, naproxen, diclofenac, meloxicam m.m.
Acetylsalicylic acid, a substance present in many medicines used to relieve pain and lower fever, and other medicines to treat pain, inflammation and fever: ibuprofen, naproxen, diclofenac, meloxicam and others;
Acetylsalicylsyre, hvis du tager mere end 3 g dagligt (smertestillende eller betændelseshæmmende lægemiddel)
Acetylsalicyclic acid if taking more than 3 g per day (medicine to relieve pain and inflammation)
Acetylsalicylsyre: Efient er beregnet til at blive administreret samtidig med acetylsalicylsyre (ASA).
Acetylsalicylic acid: Efient is to be administered concomitantly with acetylsalicylic acid (ASA).
Acetylsalicylzuur (ASA): ASA had geen invloed op de door clopidogrel geïnduceerde remming van de door ADP-geïnduceerde bloedplaatjesaggregatie; daarentegen versterkte clopidogrel wel de werking van ASA op de collageen-geïnduceerde bloedplaatjesaggregatie.
Acetylsalicylic acid (ASA): ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen-induced platelet aggregation.
Acetylsalisylsyre
Aspirin
achets integreret
(2x200)
acid Accord
Ibandronic acid Accord
Acidose, hyperkaliæmi, hypokaliæmi, hyperglykæmi, hypomagnesæmi, hypokalcæmi, hyperkolesterolæmi, hyperlipæmi, hypofosfatæmi, hyperurikæmi, arthritis urica, anoreksi
Acidosis, hyperkalaemia, hypokalaemia, hyperglycaemia, hypomagnesaemia, hypocalcaemia, hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, hyperuricaemia, gout, anorexia
Acidose, hyperkaliæmi, hypokaliæmi, hyperglykæmi, hypomagnesæmi, hypokalcæmi, hyperkolesterolæmi, hyperlipæmi, hypofosfatæmi, hyperurikæmi, artritis urica, anoreksi
Acidosis, hyperkalaemia, hypokalaemia, hyperglycaemia, hypomagnesaemia, hypocalcaemia, hypercholesterolaemia, hyperlipidaemia, hypophosphataemia, anorexia
Aclasta (medicin, der også indeholder zoledronsyre og bruges til at behandle knogleskørhed og andre ikke-kræft sygdomme i knoglerne), eller andre bisfosfonater, da den kombinerede effekt af at tage disse lægemidler sammen med Zoledronsyre Teva er ukendt.
Zometa or Aclasta (medicines that also contain zoledronic acid and are used to treat the same disease or osteoporosis and other non-cancer diseases of the bone).
Aclasta (medicin, der også indeholder zoledronsyre og bruges til at behandle knogleskørhed og andre ikke-kræft sygdomme i knoglerne), eller andre bisfosfonater, da den kombinerede effekt af at tage disse lægemidler sammen med Zometa er ukendt.
Aclasta (a medicine that also contains zoledronic acid and is used to treat osteoporosis and other non-cancer diseases of the bone), or any other bisphosphonate, since the combined effects of these medicines taken together with Zometa are unknown.
Aclasta (N=1.065) hændelses- rate (%)
Aclasta (N=1,065) event rate (%)
Aclasta (N=3.875) hændelses- rate (%)
Aclasta (N=3,875) event rate (%)
Aclasta 5 mg infusionsvæske, opløsning er klar til brug.
Aclasta 5 mg solution for infusion is ready for use.
Aclasta 5 mg infusionsvæske, opløsning zoledronsyre
Aclasta 5 mg solution for infusion Zoledronic acid
Aclasta Aclasta
Aclasta
Aclasta anvendes også til at behandle Pagets knoglesygdom hos voksne.
Aclasta is also used to treat Paget’s disease of the bone in adults.
Aclasta blev undersøgt hos mænd og kvinder i alderen over 30 år med primært mild til moderat Pagets sygdom af knoglerne (gennemsnitlig serum alkalisk fosfatase niveau på 2,6-3,0 gange den øvre grænseværdi for det normale aldersspecifikke referenceområde ved inklusion i studiet) bekræftet ved radiografisk påvisning.
Aclasta was studied in male and female patients aged above 30 years with primarily mild to moderate Paget’s disease of the bone (median serum alkaline phosphatase level 2.6–3.0 times the upper limit of the age-specific normal reference range at the time of study entry) confirmed by radiographic evidence.
Aclasta bruges også til patienter, der for nylig har brækket deres hofte ved et mindre uheld, fx ved fald, og som derfor har risiko for yderligere knoglebrud.
Zoledronic acid Teva Pharma is also used in patients who have recently broken their hip in a minor trauma such as a fall and therefore are at risk of subsequent bone breaks.
Aclasta er en klar, farveløs væske.
Aclasta is a clear and colourless solution.
Aclastas sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of Aclasta in children and adolescents below 18 years of age have not been established.
Aclidinium (aclidiniumbromid)
Aclidinium (aclidinium bromide)
Aclidinium er en kompetitiv, selektiv muskarin receptor-antagonist, med en længere opholdstid ved M3-receptorerne end M2-receptorerne.
Aclidinium is a competitive, selective muscarinic receptor antagonist, with a longer residence time at the M3 receptors than the M2 receptors.
Aclidiniumbromid er en bronkodilatator til vedligeholdelsesbehandling, og må ikke bruges til behandling af akutte episoder med bronkospasme, dvs. som anfaldsbehandling.
Aclidinium bromide is a maintenance bronchodilator and should not be used for the relief of acute episodes of bronchospasm, i.e. as a rescue therapy.
Aclidiniumbromid er en kompetitiv, selektiv muskarin receptor-antagonist (også kendt som et anticholinergikum), med en længere opholdstid ved M3-receptorerne end M2-receptorerne.
Aclidinium bromide is a competitive, selective muscarinic receptor antagonist (also known as an anticholinergic), with a longer residence time at the M3 receptors than the M2 receptors.
Aclidiniumbromid hydrolyseres hurtigt og ekstensivt til dets farmakologisk inaktive alkohol- og kulstofsyrederivater.
Aclidinium bromide is rapidly and extensively hydrolysed to its pharmacologically inactive alcohol- and carboxylic acid-derivatives.
Aclidiniumbromid kan i mindre grad påvirke evnen til at føre motorkøretøj eller betjene maskiner.
Aclidinium bromide may have minor influence on the ability to drive and use machines.
Aclidiniumbromid kan i mindre grad påvirke evnen til at føre motorkøretøj eller betjene maskiner.
Aclidinium bromide may haveminor influence on the ability to drive and use machines.
Aclidiniumbromid udviste lineær og tidsuafhængig farmakokinetik i det terapeutiske interval.
Aclidinium bromide demonstrated kinetic linearity and a time-independent pharmacokinetic behaviour in the therapeutic range.
Acne (N), seborré (N)
Acne (N), Seborrhoea (N)
Acne Alopeci Eksfoliativ dermatitis Tør hud Knuder
Acne Alopecia Dermatitis exfoliative Dry skin Skin mass
Acne Eksem
Acne Eczema
Acne Hyperhidrose
Acne Hyperhidrosis
Acne Hyperhidrose Blister Neglelidelse
Acne Hyperhidrosis Blister
Acne, allergisk kontaktdermatitis, kontaktdermatitis, dermatitis, tør hud, smerter i huden, ubehag i huden, papuløst udslæt, rosacea, hudirritation, varm hud, hævelser i ansigtet*, urticaria*.
Acne, allergic contact dermatitis, contact dermatitis, dermatitis, dry skin, pain of skin, skin discomfort, rash papular, rosacea, skin irritation, skin warm, swelling face*, urticaria
Acne, alopeci
Acne, alopecia
Acne, fedtet hud
Acne, oily skin
acne, hudlæsioner, kløe feber, kulderystelser, alment ubehag
acne, skin lesions, itching fever, chills, malaise
acne, rød eller kløende eller marmoret hud, udslæt på infusionsstedet
acne, red or itchy or mottled skin, rash at the infusion site
acne, øget svedtendens, hududslæt
acne, increased sweating, skin rash
ACOMPLIA 20 mg filmovertrukne tabletter
ACOMPLIA 20 mg film-coated tablets
ACOMPLIA 20 mg filmovertrukne tabletter rimonabant
ACOMPLIA 20 mg film-coated tablets rimonabant
ACOMPLIA anvendes som supplement til diæt og motion til behandling af voksne patienter: som er adipøse (svært overvægtige) og med et kropsmasseindeks (BMI) større end eller lig med 30 kg/m², eller som er overvægtige (med et BMI større end eller lig med 27 kg/m²), og som også har en eller flere andre risikofaktorer som f.eks. type 2-diabetes eller dyslipidæmi (unormalt højt fedtindhold i blodet).
ACOMPLIA is used together with diet and exercise to treat adult patients: who are obese (very overweight) with a body mass index (BMI) greater than or equal to 30 kg/m², who are overweight (with a BMI greater than or equal to 27 kg/m²) and also have other risk factors, such as type 2 diabetes or dyslipidaemia (abnormal levels of fat in their blood).
ACOMPLIA bør tages en gang dagligt om morgenen før morgenmaden.
ACOMPLIA should be taken once daily in the morning before breakfast.
ACOMPLIA er dråbeformet, hvide filmovertrukne tabletter mærket med ”20” på den ene side.
ACOMPLIA 20 mg is supplied as teardrop-shaped, white film-coated tablets debossed with “20”on one side.
ACOMPLIA har ikke vist påvirkning af laboratorietestværdier.
ACOMPLIA has not been shown to alter laboratory test values.
ACOMPLIA indeholder laktose.
ACOMPLIA tablets include lactose.
ACOMPLIAs udseende og pakningstørrelse
What ACOMPLIA looks like and contents of the pack
aCox proportional hazard bStratificeret af geografisk region, HER2/neu-status og tidligere capecitabinbehandling.
aCox proportional hazard bStratified by geographic region, HER2/neu status, and prior capecitabine therapy.
ACR 20 respons*
ACR 20
ACR 20 respons*
ACR 20 response
ACR 20 respons, N (%)
ACR 20 response, N (%)
ACR 20/50/70-respons blev opretholdt efter uge 24.
ACR 20/50/70 responses were maintained at Week 24.
ACR 30
ACR30
ACR 50
50
ACR 50
ACR50
ACR 50 respons*
275 (94.2%) ab
ACR 50 respons*
ACR 50 response
ACR 50 respons, N (%)
ACR 50 response, N (%)
ACR 70
ACR70
ACR 70 respons*
ACR 70
ACR 70 respons*
ACR 70 response
ACR 70 respons, N (%)
ACR 70 response, N (%)
ACR 90
ACR90
ACR respons
242 (80.4%) a
ACR respons (% af patienter)
ACR response (% of patients)
ACR Responsa
ACR 20
ACR Responsa
ACR Responsesa
ACR-30
ACR 30
ACR-50
ACR 50
ACR-70
ACR 70
ACR-N anvender de samme kriterier som ACR20, beregnet ved at tage den laveste procentvise forbedring i antallet af hæ vede led, antallet af ømme led og medianen af de sidste 5 komponenter af ACR responset.
ACR-N uses the same criteria as the ACR20, calculated by taking the lowest percent improvement in swollen joint count, tender joint count, and the median of the remaining 5 components of the ACR response.
ACR-respons i placebokontrollerede psoriasisartrit-studier (Procentdel af patienter)
ACR Response in Placebo-Controlled Psoriatic Arthritis Studies (Percent of Patients)
ACR-respons i placebokontrollerede studie (Procent af patienter)
ACR Responses in Placebo-Controlled Trials (Percent of Patients)
ACR-respons i placebokontrollerede studier (Procent af patienter)
ACR Responses in Placebo-Controlled Trials (Percent of Patients)
ACR-respons i studie V var konsistent med hensyn til DAS28- scoren.
The ACR responses in Study V were consistent with the DAS28 score.
ACR-responsa
ACR Responsesa
ACR-response
ACR response
ACR20
58.8
ACR20
ACR 20
ACR20
Responsesa
ACR20 p-værdi*
ACR 20 p-value
ACR20-respons n (%)
ACR20 response n (%)
ACR50
ACR 50
ACR50 p-værdi*
ACR 50 p-value
ACR50 uge 24
ACR50 Week 24
ACR70
ACR 70
ACR70 p-værdi*
ACR 70 p-value
ACR70 uge 24
ACR70 Week 24
Acrochordon (stilkevorter/skin tag)
Acrochordon (skin tags)
ACT I og ACT III undersøgte virkningen af BRINAVESS i behandlingen af patienter med vedvarende atrieflimren >3 timer men ikke af mere end 45 dages varighed.
ACT I and ACT III studied the effect of BRINAVESS in the treatment of patients with sustained atrial fibrillation > 3 hours but not more than 45 days in duration.
ACT II undersøgte virkningen af BRINAVESS hos patienter, som udviklede atrieflimren med varighed <3 dage efter nylig koronar bypasskirurgi (CABG) og/eller valvulær kirurgi (atrieflimren forekom >1 dag men <7 dage efter kirurgi).
ACT II examined the effect of BRINAVESS on patients who developed atrial fibrillation of < 3 days duration after recently undergoing coronary artery bypass graft, (CABG) and/or valvular surgery (atrial fibrillation occurred more than 1 day but less than 7 days after surgery).
ACT steg hos alle patienter – fra nyfødte til større børn samt voksne – i takt med stigende koncentration af bivalirudin.
The ACT increased in all patients – from neonates to older children as well as adults- with increasing bivalirudin concentrations.
ACT-værdien er positivt korreleret med dosis og plasmakoncentrationen af den indgivne mængde bivalirudin.
The ACT value is positively correlated with the dose and plasma concentration of bivalirudin administered.
Actavis ehf.
Manufacturer Actavis ehf.
Actavis Group PTC ehf 220 Hafnarfjörður
Actavis Group PTC ehf.
Actavis Group PTC ehf.
Actavis Group PTC ehf. (logo)
Actavis Group PTC ehf. [logo]
Actavis Group PTC ehf.
Actavis Group PTC ehf. [logo]
Actavis Group PTC ehf. (logo)
Actavis hf.
Actavis ehf.
Actavis Ltd BLB16
Actavis Ltd.
Actelion Danmark.
Actelion Danmark,
Actelion Pharmaceuticals Eλλάς Α.Ε. Τηλ: +30-(0)210 675 25 00
Actelion Pharmaceuticals Eλλάς Α.Ε. Τηλ: +30 210 675 25 00
Actelion Pharmaceuticals UK Ltd Tel: +44208 987 3333
Actelion Pharmaceuticals UK Ltd Tel: +44 208 987 3333
Actelion Registration Ltd.
Actelion Registration Ltd
Actelsar HCT 40 mg/12,5 mg én gang dagligt er til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med telmisartan 40 mg
Actelsar HCT 40 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 40 mg
Actelsar HCT 80 mg/12,5 mg tabletter
Actelsar HCT 80 mg/12.5 mg tablets
Actelsar HCT 80 mg/12,5 mg én gang dagligt er til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med telmisartan 80 mg
Actelsar HCT 80 mg/12.5 mg may be administered once daily in patients whose blood pressure is not adequately controlled by telmisartan 80 mg
Actelsar HCT 80 mg/25 mg én gang dagligt er til patienter, hvis blodtryk ikke kan reguleres tilfredsstillende med Actelsar HCT 80 mg/12,5 mg, eller til patienter, som tidligere er blevet stabiliseret med telmisartan eller hydrochlorthiazid hver for sig.
Actelsar HCT 80 mg/25 mg may be administered once daily in patients whose blood pressure is not adequately controlled by Actelsar HCT 80 mg/12.5 mg or in patients who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Actelsar HCT er et ‘generisk lægemiddel’.
Actelsar HCT is a ‘generic medicine’.
Actelsar HCT findes ligeledes med dosisstyrke 40 mg/12,5 mg og 80 mg/ 25 mg
Actelsar HCT is also available at the dose strengths 40 mg/12.5 mg and 80 mg/25 mg
Actelsar HCT findes ligeledes med dosisstyrke 80 mg/12,5 mg og 80 mg/ 25 mg
Actelsar HCT is also available at the dose strengths 80 mg/ 12.5 mg and 80 mg/25 mg
Actelsar HCT gives, hvis blodtrykket ikke kan reguleres tilfredsstillende med telmisartan alene.
Actelsar HCT should be used in patients whose blood pressure is not adequately controlled by telmisartan alone.
Actelsar HCT’s sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of Actelsar HCT in children and adolescents aged below 18 have not been established.
Acticam 5 mg/ml injektionsvæske, opløsning til hund og kat
Acticam 5 mg/ml solution for injection for dogs and cats
Acticam er effektivt til lindring af inflammation og smerter ved både akutte og kroniske lidelser i bevægeapparatet og til begrænsning af postoperative smerter efter ortopædiske operationer og bløddelskirurgi hos hunde og til begrænsning af postoperative smerter efter ovariehysterektomi og mindre bløddelskirurgi hos katte.
Acticam is efficacious in alleviating the inflammation and pain in both acute and chronic musculo- skeletal disorders and reducing the post operative pain following orthopaedic and soft tissue surgery in dogs and in reducing the post-operative pain after ovariohysterectomy and minor soft tissue surgery in cats.
Acticam er et ‘generisk lægemiddel’: Det betyder, at Acticam ligner et ’referenceveterinærlægemiddel’, som allerede er godkendt i EU (Metacam 1,5 mg/ml oral suspension).
Acticam is a ‘generic’: this means that Acticam is similar to a ‘reference veterinary medicine’ already authorised in the EU (Metacam 1.5 mg/ml oral suspension).
Acticam indeholder meloxicam, som tilhører en lægemiddelgruppe, der kaldes ikke-steroide antiinflammatoriske lægemidler (NSAID'er).
Acticam contains meloxicam, which belongs to a class of medicines called non-steroidal anti- inflammatory drugs (NSAIDs).
Acticam må ikke gives til dyr, som lider af gastrointestinale eller blødningsmæssige forstyrrelser, eller som har nedsat nyre- eller leverfunktion, dyr med kendt overfølsomhed over for NSAID’er eller dyr, som er under 6 uger gamle, eller katte på under 2 kg.
Acticam should also not be used in animals suffering from gastrointestinal or hemorrhagic disorders and impaired renal or hepatic function, animals with known hypersensitivity to NSAIDs, and animals less than 6 weeks of age or in cats of less than 2 kg.
Actinobacillus pleuropneumoniae, Pasteurella multocida og Haemophilus parasuis.
Actinobacillus pleuropneumoniae, Pasteurella multocida and Haemophilus parasuis.
ACTIVE-A-studiet (N = 7.554) var et multicenter, randomiseret, dobbeltblindt, placebokontrolleret 12 studie, som sammenlignede clopidogrel 75 mg / dag + ASA (N = 3.772) med placebo + ASA (N = 3.782).
The ACTIVE-A study (N=7,554) was a multicenter, randomized, double-blind, placebo-controlled study which compared clopidogrel 75 mg/day + ASA (N=3,772) to placebo + ASA (N=3,782).
ACTIVE-W-studiet viste, antikoagulansbehandling med vitamin K-antagonister var mere effektiv end med clopidogrel og ASA.
The ACTIVE-W study demonstrated that anticoagulant treatment with vitamin K antagonists was more effective than with clopidogrel and ASA.
Activyl 100 mg spot-on, opløsning, til miniaturehunde
Activyl 100 mg spot-on solution for very small dogs
Activyl 100 mg spot-on, opløsning, til miniaturehunde (under 6,5 kg) Activyl 150 mg spot-on, opløsning, til små hunde (6,6 til 10 kg)
Activyl 100 mg spot-on solution for very small dogs (less than 6.5 kg) Activyl 150 mg spot-on solution for small dogs (6.6 to 10 kg)
Activyl 100 mg spot-on, opløsning, til små katte
Activyl 100 mg spot-on solution for small cats
Activyl 100 mg spot-on, opløsning, til små katte Activyl 200 mg spot-on, opløsning, til store katte
Activyl 100 mg spot-on solution for small cats Activyl 200 mg spot-on solution for large cats
Activyl 100 mg spot-on, opløsning, til små katte Activyl 200 mg spot-on, opløsning, til store katte Indoxacarb
Activyl 100 mg spot-on solution for small cats Activyl 200 mg spot-on solution for large cats indoxacarb
Activyl 150 mg spot-on, opløsning, til små hunde
Activyl 150 mg spot-on solution for small dogs
Activyl 200 mg spot-on, opløsning, til store katte
Activyl 200 mg spot-on solution for large cats
Activyl 300 mg spot-on, opløsning, til mellemstore hunde
Activyl 300 mg spot-on solution for medium dogs
Activyl 300 mg spot-on, opløsning, til mellemstore hunde (10,1 til 20 kg) Activyl 600 mg spot-on, opløsning, til store hunde (20,1 til 40 kg) Activyl 900 mg spot-on, opløsning, til ekstra store hunde (40,1 til 60 kg)
Activyl 300 mg spot-on solution for medium dogs (10.1 to 20 kg) Activyl 600 mg spot-on solution for large dogs (20.1 to 40 kg) Activyl 900 mg spot-on solution for extra large dogs (40.1 to 60 kg)
Activyl 600 mg spot-on, opløsning, til store hunde
Activyl 600 mg spot-on solution for large dogs
Activyl 900 mg spot-on, opløsning, til ekstra store hunde
Activyl 900 mg spot-on solution for extra large dogs
Activyl må ikke udledes i vandløb, da indoxacarb kan være farligt for fisk og andre organismer i vandet.
Activyl should not be allowed to enter surface waters as indoxacarb may have harmful effects on aquatic organisms.
Activyl må ikke udledes i vandløb.
The veterinary product should not be allowed to enter surface waters.
Activyl spot-on, opløsning, til ekstra store hunde
Activyl spot-on solution for extra large dogs
Activyl spot-on, opløsning, til hunde
Activyl spot-on solution for dogs
Activyl spot-on, opløsning, til kat
Activyl spot-on solution for cats
Activyl spot-on, opløsning, til mellemstore hunde
Activyl spot-on solution for medium dogs
Activyl spot-on, opløsning, til miniaturehunde
Activyl spot-on solution for very small dogs
Activyl spot-on, opløsning, til små hunde
Activyl spot-on solution for small dogs
Activyl spot-on, opløsning, til små katte
Activyl spot-on solution for small cats
Activyl spot-on, opløsning, til store hunde
Activyl spot-on solution for large dogs
Activyl spot-on, opløsning, til store katte
Activyl spot-on solution for large cats
Activyl Tick Plus anvendes til behandling af loppeangreb hos hunde.
Activyl Tick Plus is used to treat flea infestations in dogs.
Activyl Tick Plus er et veterinærlægemiddel, der indeholder de aktive stoffer indoxacarb og permethrin.
Activyl Tick Plus is a veterinary medicine that contains the active substances indoxacarb and permethrin.
Activyl Tick Plus må ikke anvendes til katte.
Activyl Tick Plus must not be used in cats.
Activyl Tick Plus må ikke udledes i overfladevand, da indoxacarb og permethrin kan være farlige for organismer i vandet
Activyl Tick Plus should not be allowed to enter surface waters as indoxacarb and permethrin may have harmful effects on aquatic organisms.
Activyl Tick Plus må ikke udledes i overfladevand, da indoxacarb og permethrin kan være farlige for organismer i vandet.
Activyl Tick Plus should not be allowed to enter surface waters as indoxacarb and permethrin may have harmful effects on aquatic organisms.
Activyl Tick Plus spot-
Activyl Tick Plus spot- on solution for medium dogs
Activyl Tick Plus spot- on, opløsning, til ekstra store hunde
Activyl Tick Plus spot- on solution for extra large dogs
Activyl Tick Plus spot- on, opløsning, til miniaturehunde
Activyl Tick Plus spot- on solution for very small dogs
Activyl Tick Plus spot- on, opløsning, til små hunde
Activyl Tick Plus spot- on solution for small dogs
Activyl Tick Plus spot- on, opløsning, til store hunde
Activyl Tick Plus spot- on solution for large dogs
Activyl Tick Plus spot-on, opløsning, til ekstra store hunde
Activyl Tick Plus spot-on solution for extra large dogs
Activyl Tick Plus spot-on, opløsning, til hunde
Activyl Tick Plus Spot-on solution for dogs
Activyl Tick Plus spot-on, opløsning, til mellemstore hunde
Activyl Tick Plus spot-on solution for medium dogs
Activyl Tick Plus spot-on, opløsning, til miniaturehunde
Activyl Tick Plus spot-on solution for very small dogs
Activyl Tick Plus spot-on, opløsning, til miniaturehunde Activyl Tick Plus spot-on, opløsning, til små hunde Activyl Tick Plus spot-on, opløsning, til mellemstore hund Activyl Tick Plus spot-on, opløsning, til store hunde Activyl Tick Plus spot-on, opløsning, til ekstra store hunde
Activyl Tick Plus spot-on solution for very small dogs Activyl Tick Plus spot-on solution for small dogs Activyl Tick Plus spot-on solution for medium dogs Activyl Tick Plus spot-on solution for large dogs Activyl Tick Plus spot-on solution for extra large dogs
Activyl Tick Plus spot-on, opløsning, til små hunde
Activyl Tick Plus spot-on solution for small dogs
Activyl Tick Plus spot-on, opløsning, til store hunde
Activyl Tick Plus spot-on solution for large dogs
Actos 15 mg tabletter Actos 30 mg tabletter Actos 45 mg tabletter
Actos 15 mg tablets Actos 30 mg tablets Actos 45 mg tablets
Actos 15 mg tabletter Actos 30 mg tabletter Actos 45 mg tabletter Pioglitazon
Actos 15 mg tablets Actos 30 mg tablets Actos 45 mg tablets Pioglitazone
Actos 15 mg tabletter er hvide til grålighvide, runde, konvekse tabletter, der er mærkede med ‘15’ på den ene side og ‘ACTOS’ på den anden side.
Actos 15 mg tablets are white to off white, round, convex tablets marked ‘15’ on one face and ‘ACTOS’ on the other face.
Actos 15 mg tabletter Pioglitazon
Actos 15 mg tablets Pioglitazone
Actos 30 mg tabletter er hvide til grålighvide, runde, flade tabletter, der er mærkede med ‘30’ på den ene side og ‘ACTOS’ på den anden side.
Actos 30 mg tablets are white to off white, round, flat tablets marked ‘30’ on one face and ‘ACTOS’ on the other face.
Actos 30 mg tabletter Pioglitazon
Actos 30 mg tablets Pioglitazone